Join the @ASPIRE_CoP in person at #ASCO26 for “From Needs to Action: Connecting the Dots”: multidisciplinary discussion on IOTOX service lines, digital health, the ASPIRE Registry, AI innovation in irAEs & mentorship. @ASCO
📅 May 30, 2026
🕖 4:30–6:00 PM CST
📍Room S501abc
🔥 Exciting sessions to watch out for at #ASCO26!
🛡️ High-risk patients deserve immunotherapy too. How do we get them there safely?
📋 Advancing ICI Therapy in High-Risk Populations
🗓️ Mon Jun 1
🕖4:45–6:00 PM CT
📍 Room E450a
#irAEs#immunotherapy
Big morning for #irAE research at #ASCO26
📍Hall A is full of it!
A few we're watching: ICI rechallenge after irAE (#11127), CAR-T thyroid toxicity (#11148), and pan-cancer genomic drivers of irAEs (#11132). Go see them!
🔥 Exciting sessions to watch out for at #ASCO26!
⚔️ Bispecifics are powerful — and so are their toxicities. Grab the management playbook.
📋 Management of Bispecific Antibody Toxicities
🗓️ Sun May 31
🕞 11:30 AM–12:45 PM CT
📍 Room E450a
#irAEs
🫁 Severe checkpoint inhibitor pneumonitis on steroids alone? Fresh phase 2 data on add-on ruxolitinib.
🎙️ Dr. Yan Xu · Peking Union Medical College Hospital
🗓️ Sun May 31 · 9:06 AM CT
📍 Room S403
#ASCO26#irAEs#LungCancer
Using all our resources for irAE: @afreenshariffmd identifies areas that AI can accelerate care for irAEs with agentic PRO and follow up @ASPIRE_CoP#ASCO26
Building an IOTOX service line @kreynoldsMD@ASPIRE_CoP#ASCO26
➡️align with institutional priorities
➡️name your program
➡️meet regularly and invite broadly
➡️connect to the scientific community
➡️start somewhere, a pilot project etc
➡️partner with patients
@afreenshariffmd
🧪 New agents → new adverse events. Time to get comfortable with the unfamiliar.
📋 From Novel Agents to Novel Adverse Events: Toxicity Profiles of Emerging Anticancer Therapy
🗓️ Sat May 30
🕒8:00–9:15 AM CT
📍 Room S403
#ASCO26#irAEs#Immunotherapy